Cargando…

Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome

INTRODUCTION: Myelitis is the least common neuropsychiatric manifestation in systemic lupus erythematosus (SLE). Magnetic resonance imaging (MRI)-negative myelitis is even rarer. Here, we present the largest cohort of MRI-negative lupus myelitis cases to assess their clinical and immunological profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Shambaditya, Ray, Biman Kanti, Chakraborty, Arka Prava, Banerjee, Abhirup, Pandit, Alak, Das, Gautam, Dubey, Souvik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659815/
https://www.ncbi.nlm.nih.gov/pubmed/36388234
http://dx.doi.org/10.3389/fneur.2022.968322
_version_ 1784830282044538880
author Das, Shambaditya
Ray, Biman Kanti
Chakraborty, Arka Prava
Banerjee, Abhirup
Pandit, Alak
Das, Gautam
Dubey, Souvik
author_facet Das, Shambaditya
Ray, Biman Kanti
Chakraborty, Arka Prava
Banerjee, Abhirup
Pandit, Alak
Das, Gautam
Dubey, Souvik
author_sort Das, Shambaditya
collection PubMed
description INTRODUCTION: Myelitis is the least common neuropsychiatric manifestation in systemic lupus erythematosus (SLE). Magnetic resonance imaging (MRI)-negative myelitis is even rarer. Here, we present the largest cohort of MRI-negative lupus myelitis cases to assess their clinical and immunological profiles and outcome. METHOD: A single-center, observational study conducted over a period of 5 years (2017–2021) was undertaken to evaluate patients with MRI-negative lupus myelitis for the epidemiological, clinical, immunological, and radiological features at baseline and followed up at monthly intervals for a year, and the outcomes were documented. Among the 22 patients that presented with MRI-negative myelopathy (clinical features suggestive of myelopathy without signal changes on spinal-cord MRI [3Tesla], performed serially at the time of presentation and 7 days, 6 weeks, and 3 months after the onset of symptoms), 8 patients had SLE and were included as the study population. RESULTS: In 8 of 22 patients presenting with MRI-negative myelopathy, the etiology was SLE. MRI-negative lupus myelitis had a female preponderance (male: female ratio, 1:7). Mean age at onset of myelopathy was 30.0 ± 8.93 years, reaching nadir at 4.9 ± 4.39 weeks (Median, 3.0; range, 1.25–9.75). Clinically, cervical cord involvement was observed in 75% of patients, and 62.5% had selective tract involvement. The mean double stranded deoxyribonucleic acid, C3, and C4 titers at onset of myelopathy were 376.0 ± 342.88 IU/ml (median, 247.0), 46.1 ± 17.98 mg/dL (median, 47.5), and 7.3 ± 3.55 mg/dL (median, 9.0), respectively, with high SLE disease activity index 2,000 score of 20.6 ± 5.9. Anti-ribosomal P protein, anti-Smith antibody, and anti-ribonuclear protein positivity was observed in 87.5, 75, and 75% of the patients, respectively. On follow-up, improvement of myelopathic features with no or minimal deficit was observed in 5 of the 8 patients (62.5%). None of the patients had recurrence or new neurological deficit over 1-year follow-up. CONCLUSION: Persistently “MRI-negative” lupus myelitis presents with white matter dysfunction, often with selective tract involvement, in light of high disease activity, which follows a monophasic course with good responsiveness to immunosuppressive therapy. A meticulous clinical evaluation and a low index of suspicion can greatly aid in the diagnosis of this rare clinical condition in lupus.
format Online
Article
Text
id pubmed-9659815
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96598152022-11-15 Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome Das, Shambaditya Ray, Biman Kanti Chakraborty, Arka Prava Banerjee, Abhirup Pandit, Alak Das, Gautam Dubey, Souvik Front Neurol Neurology INTRODUCTION: Myelitis is the least common neuropsychiatric manifestation in systemic lupus erythematosus (SLE). Magnetic resonance imaging (MRI)-negative myelitis is even rarer. Here, we present the largest cohort of MRI-negative lupus myelitis cases to assess their clinical and immunological profiles and outcome. METHOD: A single-center, observational study conducted over a period of 5 years (2017–2021) was undertaken to evaluate patients with MRI-negative lupus myelitis for the epidemiological, clinical, immunological, and radiological features at baseline and followed up at monthly intervals for a year, and the outcomes were documented. Among the 22 patients that presented with MRI-negative myelopathy (clinical features suggestive of myelopathy without signal changes on spinal-cord MRI [3Tesla], performed serially at the time of presentation and 7 days, 6 weeks, and 3 months after the onset of symptoms), 8 patients had SLE and were included as the study population. RESULTS: In 8 of 22 patients presenting with MRI-negative myelopathy, the etiology was SLE. MRI-negative lupus myelitis had a female preponderance (male: female ratio, 1:7). Mean age at onset of myelopathy was 30.0 ± 8.93 years, reaching nadir at 4.9 ± 4.39 weeks (Median, 3.0; range, 1.25–9.75). Clinically, cervical cord involvement was observed in 75% of patients, and 62.5% had selective tract involvement. The mean double stranded deoxyribonucleic acid, C3, and C4 titers at onset of myelopathy were 376.0 ± 342.88 IU/ml (median, 247.0), 46.1 ± 17.98 mg/dL (median, 47.5), and 7.3 ± 3.55 mg/dL (median, 9.0), respectively, with high SLE disease activity index 2,000 score of 20.6 ± 5.9. Anti-ribosomal P protein, anti-Smith antibody, and anti-ribonuclear protein positivity was observed in 87.5, 75, and 75% of the patients, respectively. On follow-up, improvement of myelopathic features with no or minimal deficit was observed in 5 of the 8 patients (62.5%). None of the patients had recurrence or new neurological deficit over 1-year follow-up. CONCLUSION: Persistently “MRI-negative” lupus myelitis presents with white matter dysfunction, often with selective tract involvement, in light of high disease activity, which follows a monophasic course with good responsiveness to immunosuppressive therapy. A meticulous clinical evaluation and a low index of suspicion can greatly aid in the diagnosis of this rare clinical condition in lupus. Frontiers Media S.A. 2022-10-31 /pmc/articles/PMC9659815/ /pubmed/36388234 http://dx.doi.org/10.3389/fneur.2022.968322 Text en Copyright © 2022 Das, Ray, Chakraborty, Banerjee, Pandit, Das and Dubey. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Das, Shambaditya
Ray, Biman Kanti
Chakraborty, Arka Prava
Banerjee, Abhirup
Pandit, Alak
Das, Gautam
Dubey, Souvik
Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome
title Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome
title_full Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome
title_fullStr Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome
title_full_unstemmed Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome
title_short Persistent “MRI-negative” lupus myelitis-disease presentation, immunological profile and outcome
title_sort persistent “mri-negative” lupus myelitis-disease presentation, immunological profile and outcome
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659815/
https://www.ncbi.nlm.nih.gov/pubmed/36388234
http://dx.doi.org/10.3389/fneur.2022.968322
work_keys_str_mv AT dasshambaditya persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome
AT raybimankanti persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome
AT chakrabortyarkaprava persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome
AT banerjeeabhirup persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome
AT panditalak persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome
AT dasgautam persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome
AT dubeysouvik persistentmrinegativelupusmyelitisdiseasepresentationimmunologicalprofileandoutcome